与国家数据相比,阿巴拉契亚群体中前列腺癌呈现的严重程度增加
Marvin A Simpkins1, Garrett Douglas1, Emily Yablonsky1
1Department of Urology, Joan C Edwards School of Medicine, Huntington, WV.
Clinical genitourinary cancer
|June 13, 2025
概括
在阿巴拉契亚地区,男性更有可能被诊断为晚期前列腺癌. 这凸显了需要特定区域的战略,以改善早期检测和减少健康差异.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 健康差异 在健康上的差异
背景情况:
- 前列腺癌是美国男性癌症死亡的主要原因.
- 根据地理位置,社会经济地位和获得医疗保健的情况,前列腺癌发病率存在显著差异.
- 关于阿巴拉契亚山区内前列腺癌发病率的数据有限.
研究的目的:
- 为了研究阿巴拉契亚地区患者前列腺癌呈现的特征.
- 为了比较阿巴拉契亚患者和更大的全国队列之间的前列腺癌等级和PSA水平.
- 为了确定阿巴拉契亚人群中晚期前列腺癌的预测因素.
主要方法:
- 从一个阿巴拉契亚山脉机构 (2022-2024) 进行160次前列腺活检的回顾性审查.
- 与前列腺,肺,结肠直肠和卵巢 (PLCO) 试验中的8776个阳性活检进行比较.
- 统计分析包括千平方测试,威尔科克森等级总和测试和后勤回归来比较格里森得分,PSA水平和年龄.
主要成果:
- 与PLCO队列相比,阿巴拉契亚患者出现高度 (4级和5级) 前列腺癌的可能性显著高于PLCO队列 (19.1%和7.9%为4级;10.1%和5.0%为5级).
- 在所有格里森等级中,阿巴拉契亚患者的平均年龄和前列腺特异性抗原 (PSA) 水平较高.
- 先进的格里森等级 (4和5) 是阿巴拉契群体成员的独立预测指标,即使在调整年龄和PSA后.
结论:
- 在阿巴拉契亚地区,患者不成比例地患有晚期前列腺癌.
- 晚期疾病患病率的这种差异仍然存在,即使控制了年龄和PSA水平.
- 具体区域战略对于提高早期前列腺癌检测和缓解阿巴拉契亚地区持续存在的医疗保健差异至关重要.
更多相关视频
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
635
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.5K
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334